Changes of laboratory parameters in patients who received HU and in patients who were treated with conventional therapy
| Parameter . | Before HU treatment, median (range) . | After 6 months, median (range) . | After 12 months, median (range) . | Last follow-up, median (range) . |
|---|---|---|---|---|
| Patients on HU | ||||
| Hb, g/dL | 9.2 (5.5-12.3) | 9.8* (7.3-13.5) | 9.6* (6.8-13.5) | 9.5† (6.3-13.0) |
| MCV, fL | 71.2 (63.4-99.7) | 99.7* (77.8-133.6) | 98.4* (79.7-126.8) | 96.8* (79.8-127.2) |
| Leukocyte counts, ×109/L | 10.7 (3.0-33.8) | 7.1* (3.0-21.8) | 7.3* (3.1-20.9) | 8.0* (2.9-39.6) |
| Neutrophil counts, ×109/L | 7.6 (2.3-24.1) | 4.7* (2.0-16.3) | 4.5* (1.5-14.8) | 4.0* (1.4-22.9) |
| Platelet counts, ×109/L | 306 (100-900) | 274* (72-864) | 291* (82-815) | 308† (31-872) |
| HbF, % | 6.8 (1.0-27.4) | 21.8* (1.0-49.0) | 20.4* (3.0-49.0) | 17.4* (0.8-38.3) |
| Reticulocyte, % | 10 (1-40) | 6* (1-23) | 7* (1-35) | 6* (1-18) |
| Bilirubin, mg/dL | 1.9 (0.4-23.5) | 1.5* (0.2-23.5) | 1.5* (0.3-11.6) | 1.4* (1-18) |
| LDH, U/L | 742 (180-2180) | 633* (175-1471) | 643* (252-1904) | 636* (186-2131) |
| Patients on conventional therapy | ||||
| Hb, g/dL | 9.4 (5-14.6) | 9.0* (5.9-14.2) | 9.0* (5.5-12.8) | 9.1‡ (5.5-13.6) |
| MCV, fL | 71.4 (63.8-99.2) | 70.8 (63.2-100.2) | 70.6 (63.1-99.6) | 71.1 (62.8-99.2) |
| Leukocyte counts, ×109/L | 9.1 (2.2-33.4) | 9.1 (1.2-57.0) | 8.3* (3.3-35.9) | 9.3 (3.1-79.0) |
| Neutrophil counts, ×109/L | 5.4 (1.5-24.8) | 5.8 (0.7-43.7) | 5.5 (1.6-27.2) | 5.6 (1.6-56.8) |
| Platelet counts, ×109/L | 269 (83-888) | 325 (43-900) | 258 (89-787) | 231* (35-710) |
| HbF, % | 5.3 (0.5-32.0) | 5.0* (1.0-17.0) | 5.0* (1.0-29.0) | 4.9* (0.7-30.0) |
| Reticulocyte, % | 7 (1-40) | 8 (1-40) | 8 (2-28) | 7 (1-25) |
| Bilirubin, mg/dL | 1.9 (0.3-11.0) | 1.8 (0.3-23.5) | 2.1 (0.8-11.1) | 1.8 (0.4-38.0) |
| LDH, U/L | 680 (180-2210) | 700‡ (180-2180) | 750‡ (310-1880) | 721‡ (221-3064) |
| Parameter . | Before HU treatment, median (range) . | After 6 months, median (range) . | After 12 months, median (range) . | Last follow-up, median (range) . |
|---|---|---|---|---|
| Patients on HU | ||||
| Hb, g/dL | 9.2 (5.5-12.3) | 9.8* (7.3-13.5) | 9.6* (6.8-13.5) | 9.5† (6.3-13.0) |
| MCV, fL | 71.2 (63.4-99.7) | 99.7* (77.8-133.6) | 98.4* (79.7-126.8) | 96.8* (79.8-127.2) |
| Leukocyte counts, ×109/L | 10.7 (3.0-33.8) | 7.1* (3.0-21.8) | 7.3* (3.1-20.9) | 8.0* (2.9-39.6) |
| Neutrophil counts, ×109/L | 7.6 (2.3-24.1) | 4.7* (2.0-16.3) | 4.5* (1.5-14.8) | 4.0* (1.4-22.9) |
| Platelet counts, ×109/L | 306 (100-900) | 274* (72-864) | 291* (82-815) | 308† (31-872) |
| HbF, % | 6.8 (1.0-27.4) | 21.8* (1.0-49.0) | 20.4* (3.0-49.0) | 17.4* (0.8-38.3) |
| Reticulocyte, % | 10 (1-40) | 6* (1-23) | 7* (1-35) | 6* (1-18) |
| Bilirubin, mg/dL | 1.9 (0.4-23.5) | 1.5* (0.2-23.5) | 1.5* (0.3-11.6) | 1.4* (1-18) |
| LDH, U/L | 742 (180-2180) | 633* (175-1471) | 643* (252-1904) | 636* (186-2131) |
| Patients on conventional therapy | ||||
| Hb, g/dL | 9.4 (5-14.6) | 9.0* (5.9-14.2) | 9.0* (5.5-12.8) | 9.1‡ (5.5-13.6) |
| MCV, fL | 71.4 (63.8-99.2) | 70.8 (63.2-100.2) | 70.6 (63.1-99.6) | 71.1 (62.8-99.2) |
| Leukocyte counts, ×109/L | 9.1 (2.2-33.4) | 9.1 (1.2-57.0) | 8.3* (3.3-35.9) | 9.3 (3.1-79.0) |
| Neutrophil counts, ×109/L | 5.4 (1.5-24.8) | 5.8 (0.7-43.7) | 5.5 (1.6-27.2) | 5.6 (1.6-56.8) |
| Platelet counts, ×109/L | 269 (83-888) | 325 (43-900) | 258 (89-787) | 231* (35-710) |
| HbF, % | 5.3 (0.5-32.0) | 5.0* (1.0-17.0) | 5.0* (1.0-29.0) | 4.9* (0.7-30.0) |
| Reticulocyte, % | 7 (1-40) | 8 (1-40) | 8 (2-28) | 7 (1-25) |
| Bilirubin, mg/dL | 1.9 (0.3-11.0) | 1.8 (0.3-23.5) | 2.1 (0.8-11.1) | 1.8 (0.4-38.0) |
| LDH, U/L | 680 (180-2210) | 700‡ (180-2180) | 750‡ (310-1880) | 721‡ (221-3064) |